Complement Activation on Neisseria meningitidis
Complement Activation on Neisseria meningitidis
批准号:
8604350
负责人:
SANJAY RAM
金额:
$36.64万
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-01-01 至 2015-10-12
关键词:
AddressAffectAnimal ModelAntibioticsAntibodiesAntibody SpecificityAntigensBacteriaBindingBinding ProteinsBloodBlood CirculationCerebrospinal FluidChildClassical Complement PathwayClinicalComplementComplement 4bComplement ActivationComplement Factor BComplement Factor HComplement Membrane Attack ComplexComplexDefense MechanismsDepositionDevelopmentDiseaseEncapsulatedEpidemiologyEquilibriumFc domainFeedbackFundingGenomeGoalsGoldHealthHost DefenseHumanHybridsIgG1ImmuneImmunizationImmunoglobulin GImmunoglobulin MInactivated VaccinesInfectionInvadedKnowledgeLeadLigandsLipoproteinsMediatingMembraneMembrane ProteinsMeningococcal InfectionsMeningococcal meningitisMicrobeModelingMolecularMorbidity - disease rateMucous MembraneNasopharynxNeisseriaNeisseria meningitidisOrganismOryctolagus cuniculusOutcomePathogenesisPathway interactionsPersonsPolysaccharidesProperdinProtein BindingProteinsRecurrenceRegulationResistanceRoleSepsisSerumSiteSpecificitySurfaceSystemVaccinationVaccinesVirulencearmbactericidebaseblocking factorcapsulecomplement deficiencycomplement pathwaycomplement systemdesigndisorder preventionimprovedinhibitor/antagonistinsightkillingslipooligosaccharidemortalitynovelpathogenphosphoethanolaminepolyanionpublic health relevancevaccine candidatevaccine developmentvaccine efficacyvaccine evaluationyoung adult
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Complement (C) is a key arm of innate immune defenses against invasive meningococcal infections. Neisseria meningitidis (Nm) have evolved several sophisticated mechanisms to evade host C. A balance between the hosts' efforts to activate C on the bacterium and the microbe's C evasion strategies dictates whether the organism is cleared from the mucosa, remains an asymptomatic colonizer in the nasopharynx, or proceeds to cause invasive disease. In the previous funding period we characterized interactions between Nm and C4b, a component of the classical pathway (CP). Almost all Nm isolates recovered from the blood or cerebrospinal fluid are encapsulated and capsule is important for resistance to C. The molecular basis for capsule-mediated C resistance remains undefined. In Aim 1 will define the role of capsular polysaccharide (CPS) in regulating C. First, in Aim 1a, we will elucidate the reason for differences in the level of CP activation mediated by anti-CPS and anti-outer membrane Abs. On a molar basis, mAbs directed against CPS fix less C4b than mAbs against membrane structures, suggesting that efficient C4b binding may require activation of C4 proximate to the meningococcal molecules that serve as C4b acceptors such as LOS and opacity protein. Chimeric mAbs containing human IgG1 Fc and directed against either CPS or the Nm vaccine candidate, factor H-binding protein (fHbp) will be used to symmetrically compare the C-activating functions of these mAbs. The positive feedback loop of the alternative pathway (AP) is also important for bacterial killing by vaccine Abs. Our preliminary studies indicate that the group A, C, W-135 and Y (but not B) CPSs block activation of human C3 by purified human factors B and D. In Aim 1b we will define the molecular basis of AP inhibition by examining the interaction of CPS with purified AP components. These studies may identify a common mechanism of action for polyanions that block AP activation. AP regulation by CPS is human-specific; assembly of the rabbit AP (not regulated by CPS) will be examined in Aim 1c to provide a better understanding of the human-specificity of AP regulation by CPS. Surface proteins also contribute to C resistance; fHbp binds to the AP inhibitor, factor H (fH) and inhibits C activation. In Aim 2, we will we will exploit our knowledge of fH- fHbp interactions and use chimeric molecules to block fH binding to Nm and manipulate the C cascade to precisely define the roles of the CP and AP in killing Nm. We will also attempt to 'boost' the bactericidal function of an otherwise nonbactericidal anti-fHbp mAb (JAR 4). Such knowledge could lead to optimization of vaccine strategies. Finally, in Aim 3 we will define novel C evasion strategies in strains that express low levels of fHbp. Preliminary evidence indicates that low fHbp expressing/low fH binding Nm regulate C at the level of C5b-9 formation or insertion and we will characterize the molecular basis for C resistance at this level. These studies will help define novel mechanisms of C evasion by Nm; information that will advance understanding of meningococcal pathogenesis and improve ongoing efforts to develop effective protein-based vaccines.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1128/mbio.00949-14
发表时间:
2014-03-18
期刊:
mBio
影响因子:
6.4
作者:
[de Oliveira RB, Wang JP, Ram S, Gazzinelli RT, Finberg RW, Golenbock DT]
通讯作者:
Golenbock DT
Development of nanobody immunotherapeutics that prevent and treat gonorrhea
-
批准号:10753164
-
项目类别:
-
资助金额:$26.57万
-
财政年份:2023
-
负责人:SANJAY RAM
-
依托单位:
Gonococcal peptide vaccine candidate display using HPV virus-like particles
-
批准号:10390991
-
项目类别:
-
资助金额:$24.1万
-
财政年份:2021
-
负责人:SANJAY RAM
-
依托单位:
A novel vaccine against multidrug-resistant gonorrhea
-
批准号:10542795
-
项目类别:
-
资助金额:$29.88万
-
财政年份:2019
-
负责人:SANJAY RAM
-
依托单位:
A novel vaccine against multidrug-resistant gonorrhea
-
批准号:10083175
-
项目类别:
-
资助金额:$122.78万
-
财政年份:2019
-
负责人:SANJAY RAM
-
依托单位:
A novel vaccine against multidrug-resistant gonorrhea
-
批准号:10322115
-
项目类别:
-
资助金额:$65.31万
-
财政年份:2019
-
负责人:SANJAY RAM
-
依托单位:
An immunotherapeutic to prevent gonorrhea
-
批准号:10084961
-
项目类别:
-
资助金额:$79.85万
-
财政年份:2019
-
负责人:SANJAY RAM
-
依托单位:
Novel immunotherapeutics against multidrug-resistant Neisseria gonorrhoea
-
批准号:10207360
-
项目类别:
-
资助金额:$86.28万
-
财政年份:2017
-
负责人:SANJAY RAM
-
依托单位:
Immune defenses against Neisseria gonorrhoeae
-
批准号:9263879
-
项目类别:
-
资助金额:$62.99万
-
财政年份:2015
-
负责人:SANJAY RAM
-
依托单位:
Immune defenses against Neisseria gonorrhoeae
-
批准号:8963568
-
项目类别:
-
资助金额:$62.99万
-
财政年份:2015
-
负责人:SANJAY RAM
-
依托单位:
Vaccines and Immunotherapeutics against gonorrhea in the contex of Chlamydia co
-
批准号:9118063
-
项目类别:
-
资助金额:$49.86万
-
财政年份:2014
-
负责人:SANJAY RAM
-
依托单位:
Vaccines and Immunotherapeutics against gonorrhea in the contex of Chlamydia co
-
批准号:9331418
-
项目类别:
-
资助金额:$49.82万
-
财政年份:2014
-
负责人:SANJAY RAM
-
依托单位:
Vaccines and Immunotherapeutics against gonorrhea in the contex of Chlamydia co
-
批准号:8925769
-
项目类别:
-
资助金额:$49.81万
-
财政年份:2014
-
负责人:SANJAY RAM
-
依托单位:
Novel immunotherapeutics against multi-drug resistant Neisseria gonorrhoeae
-
批准号:8800544
-
项目类别:
-
资助金额:$25.13万
-
财政年份:2014
-
负责人:SANJAY RAM
-
依托单位:
Vaccines and Immunotherapeutics against gonorrhea in the contex of Chlamydia co
-
批准号:8914211
-
项目类别:
-
资助金额:$52.55万
-
财政年份:2014
-
负责人:SANJAY RAM
-
依托单位:
Novel immunotherapeutics against multi-drug resistant Neisseria gonorrhoeae
-
批准号:8703886
-
项目类别:
-
资助金额:$20.89万
-
财政年份:2014
-
负责人:SANJAY RAM
-
依托单位:
The alternative pathway of complement and properdin in Neisseria
-
批准号:7764292
-
项目类别:
-
资助金额:$25.14万
-
财政年份:2009
-
负责人:SANJAY RAM
-
依托单位:
ACTIVITY OF MENINGOCOCCAL VACCINE CANDIDATE GNA1870
-
批准号:7723070
-
项目类别:
-
资助金额:$0.07万
-
财政年份:2008
-
负责人:SANJAY RAM
-
依托单位:
ACTIVITY OF MENINGOCOCCAL VACCINE CANDIDATE GNA1870
-
批准号:7602064
-
项目类别:
-
资助金额:$0.11万
-
财政年份:2007
-
负责人:SANJAY RAM
-
依托单位:
Antipathogen Immunoadhesins
-
批准号:7230112
-
项目类别:
-
资助金额:$19.72万
-
财政年份:2006
-
负责人:SANJAY RAM
-
依托单位:
Complement Activation on Neisseria meningitidis
-
批准号:6836523
-
项目类别:
-
资助金额:$32.2万
-
财政年份:2004
-
负责人:SANJAY RAM
-
依托单位:
海外基金